Abstract
Introduction
Acute myelogenous leukemia (AML) originates from oncogene-transformed hematopoietic stem/progenitor cells known as leukemia stem cells (LSCs) (1) . LSCs self-renew by symmetric cell division or divide asymmetrically into a stem cell and into differentiated cells (2) . Phenotypically human LSCs in AML are a very heterogeneous population (3) . Therefore, LSCs are primarily characterized by their function and capacity to induce leukemia in xenotransplantation experiments (1, 4, 5) . From a clinical perspective, LSCs are of fundamental interest in the therapy of AML as they are resistant to existing therapeutic interventions resulting in high rates of relapse (6, 7) . As a consequence, LSC numbers or LSC gene signatures in blasts are negative predictors for survival (8, 9) . AML pathogenesis is based on serial acquisition and accumulation of various mutations in transcription factors (TFs) as well as growth factor receptor tyrosine kinases (RTKs) such as FMSrelated tyrosine kinase 3 (FLT3) (10, 11) . Signal transducer and activator of transcription (STAT) proteins are TFs involved in cytokine signaling. STATs are activated through tyrosine phosphorylation, typically through cytokine receptor-associated Janus kinases (JAKs), cytoplasmic tyrosine kinases (TKs; SRC and ABL families of kinases) or subsets of RTKs (12) . Cytoplasmic SRC, JAK and ABL TKs act upstream of STAT family of TFs (12, 13) . The STAT3/STAT5 pathway is crucial for oncogenesis in several cancer entities including leukemia (14) (15) (16) (17) ). An activating mutation in JAK2 (JAK2V617F) was identified in patients with myeloproliferative neoplasms (18). Constitutive phosphorylation of JAK2, STAT3 and/or STAT5 has been reported in AML blasts and is associated with a shorter time to relapse and poor outcome (19) (20) (21) (22) . Treatment of primary human AML cells with JAK2 and FLT3 inhibitors has resulted in reduced proliferation (23) . Recently, it has been demonstrated that JAK/STAT signaling is increased in CD34 + AML LSCs compared to normal cord blood or peripheral blood stem cells, suggesting that JAK/STAT signaling supports AML LSC growth and survival (24) . Furthermore, pSTAT5 signaling is increased and essential for maintenance of leukemic stem/progenitor cells (25) .
Therefore, targeting key TKs upstream of pSTAT3/pSTAT5 may be a promising strategy to treat AML.
A phase 2 study with the JAK2 inhibitor Ruxolitinib in relapsed/refractory AML patients showed partial clinical efficacy with complete remission (CR) in 3/38 patients (26) . However, in all patients leukemia relapsed after a short time period, indicating that inhibiting a single upstream TK may not be sufficient to eliminate LSCs. We therefore analyzed the potential of combined inhibition of several key TKs (27) , which are also known to play a role in STAT3 activation (15) . So far, Debio 0617B has documented efficacy in STAT3-driven solid tumors in vitro and in vivo (27) .
In this study, we demonstrate that pSTAT5 signaling is increased in primary AML CD34 + stem/progenitor cells compared to bulk leukemia blasts and that nuclear pSTAT3 is an independent negative prognostic factor in AML. The multi-TKI Debio 0617B reduced maintenance and self-renewal Experimental studies using the disseminated MOLM-13-Luc model were approved by the Ethics Committee for Animal Experimentation of Baden-Wuerttemberg. The experimental protocol was registered by the Regierungspräsidium Freiburg (G-11/11).
Experimental studies using MV-4-11 rat model were approved by the commission nationale de l'expérimentation animale de France.
AML patients and construction of tissue microarray (TMA)
Case selection and construction of the TMA used in the present study was described before (29) .
Briefly, bone marrow hematoxylin and eosin (H&E) slides were reviewed to confirm the diagnosis and to identify the most representative and blast-rich areas. 0.6mm punches of these areas were then removed out from the formalin-fixed, paraffin-embedded (FFPE) tissue block using a fully automated arraying device (TMA Grandmaster, 3D Histech), and a TMA block containing 222 cases was assembled.
Reagents for treatment. The compounds Debio 0617B (27) Table S1) were performed as previously described with slight modifications (31, 32 For re-exposure experiments to Debio 0617B (Fig. 4H ), total cells from primary AML colony assays were collected from the methylcellulose and 1x10 4 of these cells were re-exposed to GI 50 concentrations of Debio 0617B or vehicle in StemSpan SFEM medium overnight followed by re-plating in methylcellulose. Colonies and cells were enumerated after 14 days.
For serial re-plating experiments ( Supplementary Fig. S7 ), 10 4 cells were collected from preceding colony assays and were re-plated in methylcellulose without further addition of compound or vehicle.
Colonies were enumerated 14 days later.
MOLM-13-luc disseminated AML model. All experiments were performed using 5-6 weeks old female NSG mice. On day 22, the study was terminated, all animals sacrificed and a necropsy performed. The study consisted of 5 experimental groups (each with 10 NSG mice). On days -3 and -2, all mice were pretreated with 100 mg/kg cyclophosphamide (i.p. (two-tailed). Cut-off was determined using X-tile software a bioinformatics program for outcome-based biomarker cut-off optimization (33) . Survival time differences were plotted using Kaplan-Meier curves and analyzed using the log-rank test. After verification of the proportional hazards assumption, multiple Cox regression analysis was carried out using the continuous pSTAT3 and pSTAT5 values.
Effect size was determined using hazard ratios (HR) and 95% confidence intervals (CI), with a baseline hazard of 1.0 and a greater risk of death with HR>1.0. All p-values were two-sided and considered significant when P <0.05. Fig. S1A,B) . The frequency of pSTAT3 showed a significant positive correlation with the frequency of pSTAT5 (Supplementary Fig. S1C ). Importantly, a high frequency of pSTAT3-positive nuclei correlated with poor overall survival of AML patients (Fig. 1a) . A similar, though not statistically significant trend was observed for pSTAT5-positive nuclei ( Table S1 ). In contrast, CD45 dim SSC lo cells from BM aspirates from negative-staging biopsies from lymphoma patients (from here on termed healthy donors) which were used as controls did not express pSTAT3/pSTAT5 (Fig.
1H,I).
In the majority of AML subtypes, the disease-initiating LSCs express CD34 (1, 3, 5 
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Debio 0617B induces apoptosis in human AML cell lines.
To assess the therapeutic potential of multiple TK inhibition upstream of STAT3/STAT5 signaling, we made use of the novel SRC/JAK/ABL/Class III/V RTKs TKI Debio 0617B (N-(4-chloro-3-(2-((4- (27); Supplementary Fig. S2A ). Debio 0617B was rationally designed and synthesized on the capacity to bind the ATP binding pocket of c-SRC, JAK1, JAK2, and ABL (27) .
In order to address the degree of activity and specificity in inhibiting these kinases, we performed a cell-based kinome scan analyzing 467 different kinases. The results of the kinome scan indicated that Debio 0617B targets JAK, SRC, ABL kinases with a high degree of efficacy (Supplementary Table   S2 ). In addition, Debio 0617B targets the mutated and oncogenic form of FLT3 (FLT3-internal tandem duplication (ITD) and FLT3-D835Y), BCR-ABL, c-KIT, CSF1R, PDGFRα/β, which play a role in AML and class V RTKs (VEGFR1, 2, 3) RTKs, which play a role in the leukemic cells-stroma interaction. Table S2 Table S4 ). Debio0617B treatment strongly reduced pSTAT3/pSTAT5 signaling (Fig. 2C,D) . Importantly, total STAT3 and STAT5 levels were not affected by the Debio 0617B treatment which is in line with previous findings obtained in solid tumor models (27) . In addition, Debio 0617B increased apoptosis (Fig. 2E ) and reduced cell numbers (Fig. 2F) . Importantly, Debio 617B was more potent than any other TKI, partially targeting the key kinases upstream of STAT3/STAT5 in each of these assays (Fig. 2C-F To explore whether the effect of Debio 0617B on cell viability is mainly driven by blockade of STAT3/5 signaling, we silenced STAT3 or STAT5a genes by siRNA in MOLM-13 cells resulting in reduced STAT3 and STAT5 levels of 80-90% (Supplementary Fig. S3A ). Silencing of active STAT3 and STAT5a in MOLM-13 AML cells reduced cell viability. Importantly, siRNA-treated cells were protected from Debio 0617B-induced cell death, indicating that inhibition of STAT3/5 signaling is a main pathway for the activity of Debio 0617B (Supplementary Fig. S3B ).
(Supplementary
Debio 0617B reduces leukemia progression and prolongs survival in the MOLM-13 AML mouse model. Table S5 ). Sunitinib and Debio 0617B treatment significantly reduced leukemia progression compared to vehicle treatment as indicated by reduced levels of whole body bioluminescence 21 days after tumor injection (Fig. 3B,C) . Analysis of organspecific luminescence in peritoneum, spines, brain and lymph nodes revealed similar results (Fig. 3D and Supplementary Fig. S5A-C) . Importantly, the multi-TKI Debio 0617B reduced leukemia progression more efficiently than the TKI Sunitinib, which has a different kinase inhibition profile compared to Debio 0617B (Fig. 3B,C) . Because leukemia growth did not significantly differ between mice treated with different concentrations of Debio 0617B (Fig. 3B,C) , we selected a concentration of 10 mg/kg for all subsequent experiments. Importantly, no drug-related toxicities as assessed by Fig. S6 ).
In a second independent experiment, Debio 0671B (10 mg/kg) was additionally compared to Ruxolitinib (20 mg/kg; as JAK inhibitor comparator (40) ) and Saracatinib (25 mg/kg, as SCR/ABL inhibitor comparator (38)) (Fig. 3E-G) . After 14 days of treatment only Debio 0617B and Sunitinib reduced leukemia progression (Fig. 3F,G) . To determine whether Debio 0617B-and Sunitinib-treated mice eliminated the disease after two cycles of treatment, four animals from the Debio 0617B-treated group and all animals from the Sunitinib-treated group were kept alive after treatment discontinuation in order to monitor leukemia relapse/progression. Leukemia progressed in all animals upon drug discontinuation, indicating that the leukemia was not completely eliminated after 14 days of treatment.
However, leukemia progression was significantly slower in animals treated with Debio 0617B (Fig.   3G ). Similar results were obtained in a MV-4-11 disseminated AML mouse model. These data indicate that Debio 0617B treatment efficiently inhibits and targets leukemia cells in vivo.
Debio 0617B reduces growth and survival of primary CD34
+ AML cells in vitro.
To investigate the therapeutic potential of Debio 0617B in primary human AML, Debio 0617B was tested in liquid cultures of isolated primary human CD34 + AML stem/progenitor cells. In this context, Debio 0617B demonstrated to be highly potent with a mean GI 50 of 0.147 μM (Fig. 4A , Supplementary Table S1 ). Importantly, treatment of CD34 + and CD34 -BM cells from healthy donors (H)" revealed a mean GI 50 of 0.5 μM for Debio 0617B (Fig. 4A) . In line with the results obtained with AML cell lines (Fig. 2 and Supplementary Table S4 ), Debio 0617B treatment significantly decreased pSTAT3/pSTAT5 phosphorylation compared to vehicle treatment (Fig. 4B,C) . Importantly, Debio 0617B increased apoptosis (Fig. 4D) and reduced cell growth of human CD34 + AML cells (Fig. 4E) .
As a possibility to functionally assess the effect of Debio 0617B on stem/progenitor cells, we analyzed Fig. S7A ). Importantly, colony-forming capacity of lin -CD34 + CD90 + stem/progenitor from healthy controls was only marginally affected in serial re-plating experiments ( Supplementary   Fig. S7B ).
LSCs in AML have been previously shown to be resistant against standard treatment of care (6) . To address the question whether the remaining colony-forming cells were still sensitive to the applied treatment, surviving cells from primary colony assays were washed out of the methylcellulose and reexposed to GI 50 concentrations of Debio 0617B or vehicle overnight followed by re-plating in methylcellulose. After 14 days, re-exposure to Debio 0617B further decreased colony formation (Fig.   4H ). These experiments indicate that Debio 0617B eliminates CD34 + AML progenitor cells in vitro.
Debio 0617B eradicates human LSCs in AML patient-derived xenografts. and 149 (JAK2V617F) were transplanted into NSG mice. Two weeks later, mice were subjected to treatment with vehicle, Debio 0617B (10 mg/kg) and the narrow-spectrum TKIs Ruxolitinib (JAK inhibitor), Quizartinib (AC220, FLT3 inhibitor) and/or Sunitinib (large spectrum TKI) (Fig. 5A) . All narrow-spectrum TKI-treated mice which succumbed to the disease harbored an overt leukemia.
Debio 0617B-treated mice survived significantly longer than narrow-spectrum TKI-treated AML mice with 9/10 mice surviving long-term (Fig. 5B,C) . These data indicate that LSCs were eradicated or successfully controlled in Debio 0617B-treated mice. Importantly, no-drug-related changes in body weight as parameter of toxicity have been observed (Supplementary Fig. S8 ). an AML and all animals survived long-term without any sign of leukemia (Fig. 5D,E) . These results indicate that treatment with Debio 0617B eliminated the disease-initiating LSCs in a majority of animals.
Debio 0617B inhibits growth and self-renewal of human LSCs in vivo.
Finally, we analyzed the effect of Debio 0617B treatment on disease-initiating CD34 + AML LSCs in vivo. CD34 + AML cells from patient 145 (FLT3-ITD) were transplanted into NSG mice. Two weeks later, Debio 0617B, Ruxolitinib, Quizartinib (AC220) or Sunitinib were administered by gavage for two weeks. Debio 0617B treatment significantly reduced spleen size and cellularity (Supplementary Fig.   S9 ) and reduced the percentage and absolute numbers of human AML cells in murine BM compared to controls (Fig. 6A,B) . Similar to the in vitro experiments (Fig. 2) , Debio 0167B significantly reduced pSTAT3 (Fig. 6C) and pSTAT5 (Fig. 6D) (Fig. 6E) . Importantly, Debio 0617B treatment reduced CD34 + AML LSCs (Fig. 6F ) resulting in fewer colonies in methylcellulose when compared to controls (Fig. 6G) .
In AML only LSCs are able to propagate the disease in vivo (1, 4, 5) . To further prove that the findings from FACS analysis and colony assays in vitro actually account for reduced LSC numbers in vivo, we secondarily transplanted BM cells from AML-bearing NSG mice of all treatment groups into sublethally irradiated NSG mice. All animals transplanted with BM from Debio 0617B-treated mice survived longterm, whereas mice from all single TK-treated groups died. This indicates that Debio 0617B indeed targets leukemia-initiating cells (Fig. 6H) . 
Discussion
AML is a very heterogeneous myeloid neoplasm resulting from sequential acquisition of multiple molecular abnormalities. These include various mutations in TFs as well as growth factor RTKs. As a common downstream signaling event, activated TK lead to increased signaling via STAT3/STAT5 and increased cell proliferation, survival and disease progression. Therefore, constitutive STAT3 signaling correlates with decreased disease-free survival (21). In this study, we confirmed and extended these earlier results in a large TMA analysis by showing that increased expression of pSTAT3, but not pSTAT5, is an independent negative prognostic marker for overall survival in AML patients. These results suggest that targeting STAT signaling is a promising strategy to treat AML. Unfortunately, the (Fig. 6) resulting in a marginal prolongation of survival (Fig. 5) . Only the combined inhibition of TKs by Debio 0617B completely eliminated LSCs as tested in a very sensitive re-transplantation assay in irradiated NSG mice. This indicates that Debio 0617B as single agent is highly active and eliminates LSCs by combined inhibition of multiple key TKs whereas inhibiting a single pathway is sufficiently compensated by other up-stream TKs. This is in contrast to our findings with Debio 0617B in STAT3-driven solid tumors models, where potent and sustained tumor inhibition required combination with an EGFR inhibitor (27) .
Importantly, as compared to other TKIs used in the clinical management of myeloid malignancies, our data suggest that continuous exposure to Debio 0617B is not required to control/eradicate LSCs.
However, inhibition of TKs upstream of STAT3/STAT5 also activates other compensatory signaling pathway. For example FLT3 TKI-resistant primary samples and cell lines trigger a constant activation PI3K/AKT/JAK signaling (67) and BM stromal cells induce compensatory ERK signaling in response to FLT3-ITD inhibition in AML cells (68) . A recent study suggests that a combination of FLT3 with JAK inhibitors may overcome these resistance mechanisms (62) . In addition, incomplete elimination of LSCs will lead to the acquisition of secondary resistance mutations (47), e.g. different studies reported the emergence of secondary FLT3 TK domain point mutations in response to FLT3 inhibitor therapy (69, 70) . Remarkably, in our study, even after exposure of AML mice to Debio 0617B for more up to 130 days, no resistant clones to Debio 0617B could be detected. Consequently, studying resistance mechanisms to Debio 0617B could not be assessed in this study. Overall, this data indicates that Debio 0617B rapidly and efficiently eliminates LSCs in the long-term before secondary resistance mechanisms develop. Importantly, Debio 0617B did not reduce the viability of normal hematopoietic stem-or progenitor cells nor led to toxicity in treated animals supporting the potential further 
